Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

A recent study from the Federal University of São Paulo (UNIFESP) has found that using infrared light along with regular ...

Global diabetes rates have surged, particularly in low-resource areas, revealing critical gaps in treatment access and ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Lähteenvuo notes that while more research is called for, drugs like Ozempic may offer hope to those burdened by addiction, ...

People living with HIV may also have to manage other health conditions like cardiovascular disease, type 2 diabetes, ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Fourteen percent of the world's people -- more than 800 million -- now have diabetes, a doubling of the global rate for the ...

More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment ...

The rise in type 2 diabetes cases globally presents opportunities for growth in the market for GLP-1 drugs like Ozempic and ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

Diabetes is the eighth leading cause of death in the US and can lead to other conditions, including kidney failure, ...